Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Targeting steroid receptor co-activators to inhibit breast cancer stem cells.

Truong TH, Lange CA, Ostrander JH.

Oncoscience. 2018 Aug 28;5(11-12):281-282. doi: 10.18632/oncoscience.469. eCollection 2018 Nov. No abstract available.


Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.

Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA.

Mol Cancer Res. 2018 Nov;16(11):1761-1772. doi: 10.1158/1541-7786.MCR-18-0410. Epub 2018 Jul 10.


Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes.

Truong TH, Hu H, Temiz NA, Hagen KM, Girard BJ, Brady NJ, Schwertfeger KL, Lange CA, Ostrander JH.

Mol Cancer Res. 2018 Apr;16(4):707-719. doi: 10.1158/1541-7786.MCR-17-0598. Epub 2018 Jan 18.


Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages.

Girard BJ, Knutson TP, Kuker B, McDowell L, Schwertfeger KL, Ostrander JH.

J Biol Chem. 2017 Jan 6;292(1):339-350. doi: 10.1074/jbc.M116.739847. Epub 2016 Nov 23.


Modifications to glucocorticoid and progesterone receptors alter cell fate in breast cancer.

Leehy KA, Regan Anderson TM, Daniel AR, Lange CA, Ostrander JH.

J Mol Endocrinol. 2016 Apr;56(3):R99-R114. doi: 10.1530/JME-15-0322. Epub 2016 Feb 1. Review.


Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death.

Girard BJ, Regan Anderson TM, Welch SL, Nicely J, Seewaldt VL, Ostrander JH.

PLoS One. 2015 Mar 19;10(3):e0121206. doi: 10.1371/journal.pone.0121206. eCollection 2015.


Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA.

Oncogene. 2015 Jan 22;34(4):506-15. doi: 10.1038/onc.2013.579. Epub 2014 Jan 27.


PELP1: a review of PELP1 interactions, signaling, and biology.

Girard BJ, Daniel AR, Lange CA, Ostrander JH.

Mol Cell Endocrinol. 2014 Jan 25;382(1):642-651. doi: 10.1016/j.mce.2013.07.031. Epub 2013 Aug 8. Review.


Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.

D'Amato NC, Ostrander JH, Bowie ML, Sistrunk C, Borowsky A, Cardiff RD, Bell K, Young LJ, Simin K, Bachelder RE, Delrow J, Dawson A, Yee LD, Mrózek K, Clay TM, Osada T, Seewaldt VL.

PLoS One. 2012;7(9):e45684. doi: 10.1371/journal.pone.0045684. Epub 2012 Sep 25.


Monitoring of receptor dimerization using plasmonic coupling of gold nanoparticles.

Crow MJ, Seekell K, Ostrander JH, Wax A.

ACS Nano. 2011 Nov 22;5(11):8532-40. doi: 10.1021/nn201451c. Epub 2011 Oct 25.


Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA.

Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.


Brk/PTK6 signaling in normal and cancer cell models.

Ostrander JH, Daniel AR, Lange CA.

Curr Opin Pharmacol. 2010 Dec;10(6):662-9. doi: 10.1016/j.coph.2010.08.007. Epub 2010 Sep 9. Review.


Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.

Ostrander JH, McMahon CM, Lem S, Millon SR, Brown JQ, Seewaldt VL, Ramanujam N.

Cancer Res. 2010 Jun 1;70(11):4759-66. doi: 10.1158/0008-5472.CAN-09-2572. Epub 2010 May 11.


Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines.

Millon SR, Ostrander JH, Brown JQ, Raheja A, Seewaldt VL, Ramanujam N.

Breast Cancer Res Treat. 2011 Feb;126(1):55-62. doi: 10.1007/s10549-010-0884-1.


Preferential accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in breast cancer: a comprehensive study on six breast cell lines with varying phenotypes.

Millon SR, Ostrander JH, Yazdanfar S, Brown JQ, Bender JE, Rajeha A, Ramanujam N.

J Biomed Opt. 2010 Jan-Feb;15(1):018002. doi: 10.1117/1.3302811.


CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3.


Light scattering measurements of subcellular structure provide noninvasive early detection of chemotherapy-induced apoptosis.

Chalut KJ, Ostrander JH, Giacomelli MG, Wax A.

Cancer Res. 2009 Feb 1;69(3):1199-204. doi: 10.1158/0008-5472.CAN-08-3079. Epub 2009 Jan 13.


ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.


The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.

You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC.

Carcinogenesis. 2007 Dec;28(12):2491-500. Epub 2007 Sep 3.


Regulated association of protein kinase B/Akt with breast tumor kinase.

Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA.

J Biol Chem. 2005 Jan 21;280(3):1982-91. Epub 2004 Nov 10.

Supplemental Content

Loading ...
Support Center